is there currently a research gap in MIPD vs. open pancreatoduodenectomy — 5-year OS and R0 resection rates (is this a good meta-analysis focused topic to publish on?)
Searching PubMed
minimally invasive pancreatoduodenectomy open pancreatoduodenectomy overall survival
Searching PubMed
minimally invasive pancreatoduodenectomy R0 resection oncological outcomes
Searching the Web
MIPD vs open pancreatoduodenectomy 5-year overall survival R0 resection meta-analysis research gap 2024 2025
Reading Article
Reading Article
Reading Article
Reading Article
Reading Article
Searching PubMed
minimally invasive pancreatoduodenectomy long-term survival oncological outcomes
Searching the Web
MIPD open pancreaticoduodenectomy 5-year overall survival systematic review 2024 2025 2026 published
Searching PubMed
minimally invasive open pancreatoduodenectomy NEJM Evidence 2025 periampullary
Reading Web Page
5-year overall survival R0 resection rate research gap findings
Reading Article
Searching PubMed
pancreatoduodenectomy minimally invasive "5-year" overall survival meta-analysis
Reading Article
Reading Article
I now have a comprehensive picture. Let me synthesize everything into a thorough answer.
Is There a Research Gap? Yes - Here's the Evidence
This is a well-founded and publishable topic, but the gap is more nuanced than it first appears. Here is a detailed breakdown.
What the Current Literature Actually Covers
Most meta-analyses focus on SHORT-TERM outcomes
The bulk of published systematic reviews and meta-analyses (2021-2026) on MIPD vs. OPD report:
- 90-day mortality
- Major complications (Clavien-Dindo ≥ III)
- Perioperative blood loss
- Hospital length of stay
- Pancreatic fistula rates
- Operative time
- R0 rate (margin status)
- Lymph node yield
Key papers in this space:
| PMID | Paper | Key Scope |
|---|---|---|
| 37076411 | Uijterwijk et al., EJSO 2023 | IPD meta-analysis of RCTs for PDAC - R0, LN yield, 90-day outcomes. No 5-yr OS. |
| 35641405 | Vissers et al., HPB 2022 | IPD meta-analysis of LPD RCTs. Major complications, hospital stay. No 5-yr OS. |
| 42174581 | Qutob et al., BMC Surg 2026 | 7 RCTs, GRADE evaluation - perioperative + R0 + LN. "Short-term oncological outcomes" only. No 5-yr OS. |
| 40731751 | Valle et al., Medicina 2025 | Network meta-analysis (LPD vs RPD vs OPD) from RCTs. R0, fistula, LOS. No 5-yr OS. |
| 39153714 | Neshan et al., J Gastro Surg 2024 | Robotic vs. open only - includes OS signal (robotic slightly better HR), but mostly retrospective cohorts, not RCT-based and not laparoscopic. |
| 41288428 | de Graaf et al., NEJM Evid 2025 | Most recent major RCT (288 patients, 14 centres). Primary endpoint = 90-day complications + TTFR. No long-term OS endpoint. |
The One Meta-Analysis on 5-Year OS
Kamarajah et al., HPB 2021 [PMID 33077373] is essentially the only meta-analysis that directly pooled 5-year OS after MIPD vs. OPD. Key findings:
- 31 studies, 58,622 patients (86% OPD, 14% MIPD)
- 5-yr OS: HR 0.78 (95% CI 0.50-1.22), p=0.2 - similar between groups
- PDAC-only sensitivity: HR 0.69 (95% CI 0.32-1.50), p=0.3 - still non-inferior
- Critical limitation: based almost entirely on observational, non-randomized studies (retrospective cohorts) with major selection bias
That was 2021. Since then:
- Multiple new RCTs have been published or completed
- Robotic MIPD has grown substantially (barely represented in that 2021 paper)
- New individual patient data (IPD) from RCTs is now available
- Disease-specific analyses (PDAC vs. ampullary vs. distal cholangiocarcinoma) have emerged as distinct questions
The Specific Research Gap
Here is where your meta-analysis would sit in the gap:
1. No meta-analysis has pooled 5-year OS using RCT-level data or IPD from RCTs. The Kamarajah 2021 paper used observational data only. Every RCT meta-analysis published since (Vissers 2022, Uijterwijk 2023, Qutob 2026, de Graaf 2025) explicitly stopped at 90-day endpoints.
2. R0 resection rates ARE covered in the literature - multiple meta-analyses report R0 as a short-term oncological endpoint. The Uijterwijk 2023 IPD meta-analysis showed comparable R0 rates (RD -1%, p=0.74). The 2026 Qutob BMC Surg paper also found no significant R0 difference from RCTs. So R0 alone as your primary outcome would likely be rejected by reviewers as already answered - it would need to be contextualized as a secondary outcome or as a means to understand its correlation with 5-year OS.
3. The Olvera Morales 2025 Cureus systematic review explicitly stated: "most included studies primarily reported perioperative outcomes, with limited information on long-term oncologic results such as recurrence rates, disease-free survival, and margin status. This highlights a gap in the literature."
4. The Uijterwijk 2023 EJSO paper concluded: "The impact on long-term survival and recurrence should be studied in RCTs including robotic MIPD." - a direct call for the exact work you are describing.
How Publishable Is This?
The honest assessment:
| Factor | Assessment |
|---|---|
| Gap exists? | Yes - no meta-analysis of 5-year OS from RCTs or post-2021 data |
| R0 alone publishable? | Weak standalone - already well-covered; use as secondary outcome |
| 5-year OS from RCT data? | Strong gap - very few RCTs follow patients long enough; this is the honest challenge |
| Disease-specific angle (PDAC only, or robotic only)? | Stronger angle - PDAC-specific or robotic-MIPD-specific 5-yr OS is genuinely sparse |
| Feasibility issue? | Real risk - most RCTs only report 90-day follow-up; you may be pooling mostly retrospective OS data, which reviewers will scrutinize |
The strongest publishable framing would be:
A systematic review and meta-analysis of long-term (3- and 5-year) overall survival and disease-free survival after MIPD vs. OPD, stratified by:
- Approach (laparoscopic vs. robotic)
- Histology (PDAC vs. non-PDAC periampullary)
With R0 included as a secondary oncological outcome and meta-regression for center volume.
This builds on the Kamarajah 2021 foundation but adds the post-2021 RCT data, robotic platform data, disease-specific subgroups, and GRADE evaluation - all of which are absent from that paper.
Practical Considerations
- Target journals: HPB, Annals of Surgery, EJSO, BJS, Surgical Endoscopy
- PROSPERO registration: Check whether any similar protocol is already registered (Kamarajah or Uijterwijk groups are active in this space)
- Main risk: If pooled 5-year OS data is only available from retrospective cohorts (not RCTs), the meta-analysis will face "known unknowns" - heavy heterogeneity and selection bias. You would need to clearly separate RCT-based and observational data in your analysis
- Key differentiator from Kamarajah 2021: include 2021-2026 data, separate robotic vs. laparoscopic, use IPD where available, apply GRADE, and focus on PDAC-specific subgroup
Bottom line: The gap is real, particularly for robotic MIPD and PDAC-specific 5-year OS using post-2021 evidence. R0 as an isolated outcome is less novel. A combined approach - framing 5-year OS as the primary endpoint with R0 and DFS as secondary oncological outcomes, stratified by platform and histology - gives you the strongest case for a high-impact publication.
This is a shared conversation. Sign in to Orris to start your own chat.